OnKure Announces the Appointment of Dylan Hartley as Chief Scientific Officer
2024年7月26日 - 7:43AM
OnKure, Inc. today announced that Dylan Hartley, Ph.D. has been
appointed to the position of Chief Scientific Officer. In this
position, Dr. Hartley will lead the company’s research
organization.
“Dr. Hartley has a deep commitment to innovation and advancing
drugs to improve patient care,” said Nicholas Saccomano, Ph.D.,
President and Chief Executive Officer of OnKure. “He has over 20
years of experience in drug research and development, including
deep expertise in pharmacology, toxicology, drug metabolism and
pharmacokinetics. As OnKure’s chief scientific officer, Dr. Hartley
will continue to build momentum across our PI3Kα franchise of
mutant specific programs.”
“I am delighted to be joining OnKure and being part of an
incredibly experienced team that has a long track record of
discovering and advancing life-changing treatments to the market,”
said Dr. Hartley. “I look forward to the opportunity to help bring
forward novel and innovative medicines for cancer patients by
continuing the amazing science that goes on at OnKure every
day.”
James Winkler, Ph.D., who currently serves as OnKure’s chief
scientific officer, has chosen to serve as an advisor and
consultant to the company. Dr. Winkler joined OnKure early in its
formation overseeing discovery and has helped shape OnKure’s
approach to accelerate drug discovery and development.
“We are incredibly grateful to Jim, not just for all he has done
at OnKure but for his significant contributions to the field of
oncology research overall. It’s been a great privilege to have him
lead the team here, and we’re gratified that he has agreed to
remain a part of the company in an advisory role,” said Dr.
Saccomano.
Previously, Dr. Hartley served as Vice President, Head of
Research at Pfizer Inc.’s Boulder facility (previously Array
BioPharma), where he led drug discovery research and oversaw small
molecule discovery from target identification though IND submission
and into clinical development. He holds a B.A. in
biological sciences from the University of Northern Colorado and a
Ph.D. in pharmaceutical sciences from the University of Colorado
Health Sciences Center.
About OnKure
OnKure is a clinical-stage biopharmaceutical company focused on
the discovery and development of best-in-class precision medicines
that target biologically validated drivers of cancers that are
underserved by available therapies. Using structure-based drug
design platform, OnKure is building a robust pipeline of
tumor-agnostic candidates that are designed to achieve optimal
efficacy and tolerability. OnKure is currently developing OKI-219,
a selective PI3KαH1047R inhibitor, as its lead program. OnKure aims
to become a leader in targeting oncogenic PI3Kα and has multiple
programs designed to enable best-in-class targeting of this key
oncogene.
For more information about OnKure, visit us at www.onkure.com
and follow us on LinkedIn.
Contact:
Investors:
IR@onkure.com